



LKT Laboratories, Inc.

GSK-461364

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID G7241

CAS No. 929095-18-1

Chemical Name

Synonym

Formula $C_{27}H_{28}F_3N_5O_2S$

Formula Wt. 543.60

Melting Point

Purity $\geq 99\%$

Solubility Ethanol 30 mg/mL (55.18 mM)


DMSO 10 mg/mL (18.39 mM)

Water Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description GSK-461364 is an inhibitor of polo-like kinase 1 (PLK1) that is currently in clinical trials as a potential treatment for solid tumor cancers. GSK-461364 displays anticancer chemotherapeutic activity as well as anticoagulant activity. This compound inhibits glioblastoma cell proliferation, invasion, and colony formation and induces apoptosis and G2 phase cell cycle arrest.



Bulk quantities available upon request

Product ID	Size
G7241	1 mg
G7241	5 mg
G7241	10 mg
G7241	25 mg

References Yim H. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. *Anticancer Drugs*. 2013 Nov;24(10):999-1006. PMID: 23949254.

Pezuk JA, Brassesco MS, Morales AG, et al. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. *Cancer Gene Ther*. 2013 Sep;20(9):499-506. PMID: 23887645.

Olmos D, Barker D, Sharma R, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. *Clin Cancer Res*. 2011 May 15;17(10):3420-30. PMID: 21459796.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.